The treatment is recommended in patients with systolic dysfunction, who are in sinus rhythm and whose heart rate is 75 beats per minute or more and who have a have a left ventricular ejection fraction of 35% or less.
Professor Carole Longson, NICE Health Technology Evaluation Centre Director, said “Procoralan has been shown to have a beneficial effect in reducing mortality and improving quality of life in people with some types of chronic heart failure.”
Heart failure affects approximately 900,000 people in the UK. The most common cause of heart failure is coronary heart disease.
The guidance also states that Procoralan should be taken in combination with standard therapy or when beta-blockers are contraindicated or not tolerated. Additionally, it must only be used after a stabilisation period of 4 weeks on optimised standard therapy.
“The Committee was mindful that there is robust evidence for the effectiveness of ACE inhibitors, beta-blockers and aldosterone antagonists that are used routinely in managing heart failure,” said Professor Longson.
“They concluded, therefore, that Procoralan could be considered a cost-effective use of NHS resources for treating chronic heart failure after optimal treatment with these drugs has been achieved and when patients are still symptomatic after receiving optimised initial therapies, or when beta-blockers are contraindicated or not tolerated by the patients.”